Testen van een zacht exoskelet tijdens looptaken uit het dagelijks leven; XoSoft Gamma-prototype teste
Not yet recruiting
- Conditions
- subjects with stroke and incomplete spinal cord injury
- Registration Number
- NL-OMON20675
- Lead Sponsor
- Roessingh Research and Development performs the trial in collaboration with the other partners within the European H2020 XoSoft project. Project leader: J. Ortiz, Fondazione Istituto Italiano di Tecnologia, Genova, Italy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
stroke or incomplete spinal cord, at least 6 months ago
-unilateral ( for stroke) or uni- or bilateral (for iSCI) impaired
Exclusion Criteria
-Inability to wear the prototype due to health conditions (like wounds that can give a problem when wearing the system)
-in case ankle-foot orthoses are used in daily life: inability to walk without ankle-foot orthosis for 10m
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The feasibility of the system is tested by objective qualitative and quantitative evaluation of the gait pattern data, comparing the system in Active and InActive state with the locomotion pattern without wearing the system.<br><br /><br /><br>Kinematics (hip/knee/ankle angles, foot clearance, trunk kinematics) spatiotemporal (walking speed, duration of gait phases) and control-strategy parameters (amount, timing, duration, consistency of the actuation) are evaluated.
- Secondary Outcome Measures
Name Time Method The usability of the system is tested by subjective evaluation of the opinion of participants that used the prototype. The System Usability Scale and a semi-structured interview will be used to gather information about user-experience.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What neurological pathways are targeted by soft exoskeletons in stroke and incomplete spinal cord injury rehabilitation?
How does the XoSoft Gamma-prototype compare to conventional rehabilitation methods for gait recovery in post-stroke patients?
Which biomarkers correlate with improved mobility outcomes in incomplete spinal cord injury patients using soft exoskeletons?
What adverse events are associated with soft exoskeleton use in neurologically impaired populations and how are they mitigated?
Are there synergistic effects between XoSoft Gamma-prototype and pharmacological agents like riluzole in spinal cord injury recovery?